This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Wegovy and Ozempic have the same active ingredient, semaglutide. “Technically, they are exactly the same,” Dr. Maria Daniela Hurtado Andrade, an endocrinologist at the Mayo Clinic’s ...

'ZDNET Recommends': What exactly does it mean? ZDNET's recommendations are based on many hours of testing, research, and comparison shopping. We gather data from the best available sources ...

aCardiovascular R&D Centre – UnIC@RISE, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto 4200-319, Portugal ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.